Background Establishing alternatives to lifelong chemotherapy for patients with advanced
pancreatic cancer has been proposed to address chemotherapy resistance and cumulative …

Simple Summary Approximately 10–20% of pancreatic cancer patients will have a mutation
in their DNA, passed on in families, that contributes to the development of their pancreatic …

Simple Summary Constipation is the third most common symptom in patients receiving
cytotoxic chemotherapy, and it can impact their quality of life. There is no clear definition of …

Incidence of pancreatic ductal adenocarcinoma (PDAC) is increasing over the last years,
while patients prognosis remains grim. Recently germline BRCA1 and 2 pathogenic variants …

Purpose The clinical outcome and the efficacy of chemotherapy in pancreatic cancer
patients with BRCA1/2 Variants of Unknown Significance (VUS) is unknown. We explored …

Objective BRCA1/2 are integral to the DNA repair mechanism and their germline pathogenic
variants (gBRCA) result in a high risk for developing breast and ovarian cancer. Patients …

Abstract Background Cancers of the Vater ampulla (ampullary cancers, ACs) account for
less than 1% of all gastrointestinal tumors. ACs are usually diagnosed at advanced stage …

CLL management. With the intention of minimising off-target adverse effects, new BTK
inhibitors, such as zanubrutinib and acalabrutinib, have been developed and approved for …

Background Pancreatic ductal adenocarcinoma (PDAC) harbouring germline BRCA1-2
pathogenic variants (gBRCA1-2pv) is a distinct nosological entity. Information on second …

Background Administering chemotherapy until progression to metastatic pancreatic ductal
adenocarcinoma (PDAC) patients lacks of supporting evidence and causes cumulative …